Our research findings have been published in several respected academic journals, and we have submitted a number of international patent applications. These developments have been noticed and reported on by a variety of media outlets, both local and international, such as Science Daily, Xinhua News Agency, ScienceNet.cn, China News Service, Los Angeles Times, and Australian Associated Press.
[First release] Aikai Bio announced the completion of a new round of financing to promote the continuous industrialization of super iPSCs that ”clear epigenetic memory”!
2023.08.28MORE
Congratulations! Professor Liu Xiaodong* founder of Ai Kailiyuan* has published his research results in Nature again!
2023.08.23MORE
iCamuno Biotherapeutics Ranked among the ‘2022 China Potential Unicorn Enterprises’ List!
2023.06.21MORE
Two Honors in a Row! iCamuno Biotherapeutics Continues to Gain Industry Recognition!
2023.04.19MORE
The Grand Opening of iCamuno’s GMP Manufacturing Facility in Suzhou
2023.03.13MORE
iCamuno Biotherapeutics Wins the Highest Honor in the National Disruptive Technology Innovation Contest Finals
![[First release] Aikai Bio announced the completion of a new round of financing to promote the continuous industrialization of super iPSCs that ”clear epigenetic memory”!](/uploads/image/news/230828-0947.png)
